Liquid biopsy for the detection of clinical biomarkers in early breast cancer: new insights and challenges

2020 ◽  
Vol 21 (5) ◽  
pp. 359-367
Author(s):  
Akiko Matsutani ◽  
Chihiro Udagawa ◽  
Yuki Matsunaga ◽  
Seigo Nakamura ◽  
Hitoshi Zembutsu
Keyword(s):  
Breast Cancer ◽  
Early Diagnosis ◽  
Liquid Biopsy ◽  
Clinical Utility ◽  
Detection Method ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Screening Programs ◽  
Clinical Biomarkers ◽  
Life Threatening

The widespread use of breast screening programs has contributed to the detection of early stage breast cancer, which is often asymptomatic. Early diagnosis is essential to avoid overtreatment and improve clinical outcomes, as early stage breast cancer is rarely life-threatening if detected quickly. Despite this, tissue biopsy remains the principle method for detecting these cancers. Liquid biopsy has been recently proposed as a promising detection method in oncology that is not only less invasive but also contributes to the early diagnosis of breast cancer. Here, we describe the clinical utility of liquid biopsy as a tool for the early detection of breast cancer.

Abstract LB-226: Exosomal liquid biopsy reveals mRNA and lincRNA biomarkers in early stage breast cancer patient plasma

2018 ◽  
Author(s):  
Sudipto K. Chakrabortty ◽  
Robert R. Kitchen ◽  
Christine M. Coticchia ◽  
Vasisht R. Tadigotla ◽  
Erez Eitan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Liquid Biopsy ◽  
Early Stage ◽  
Early Stage Breast Cancer

High levels of proliferation regulators and an impaired senescence response pathway to identify early-stage breast tumors with a poor prognosis.

2013 ◽  
Vol 31 (26_suppl) ◽  
pp. 43-43
Author(s):  
Fiona T. Lanigan ◽  
Eiseart J. Dunne ◽  
Gerard L. Brien ◽  
Fatima Al Oraifi ◽  
Yue Fan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Primary Cultures ◽  
Cancer Recurrence ◽  
Recurrence Risk ◽  
Early Stage Breast Cancer ◽  
Breast Cancer Patients ◽  
Cancer Proliferation ◽  
Protein Levels ◽  
Clinical Biomarkers

43 Background: Predicting the risk of tumour recurrence, and thus the need for chemotherapy, for lymph node-negative breast cancer patients is a significant problem for clinicians and patients. Methods: We have identified a ‘core proliferation signature,’ which is consistently high in proliferating primary cultures, and is downregulated during cellular senescence. Using a reverse engineering approach on a breast cancer-specific regulatory network, and confirmed by ChIP-seq analysis, we have identified a hierarchy of several highly interconnected Master Transcriptional Regulators upstream of these core proliferation genes. Results: Further analysis of the expression of these factors in breast cancer cohorts at the mRNA and protein levels reveals a remarkable ability to reliably predict recurrence risk for early-stage breast cancer. Strikingly, in our analyses, a combination of just two of these factors outperforms the currently used clinical biomarkers for breast cancer recurrence risk, as well as recently developed multi-gene prognostic assays. Moreover, the addition of the senescence regulator p16INK4A to this panel further increases its prognostic capability. Conclusions: We propose that this novel approach has succeeded in identifying ‘drivers’ of breast cancer proliferation which, when combined with a marker of senescence such as p16INK4A, successfully identify actively proliferating tumours with an impaired senescence response pathway. Furthermore, we suggest that this gene combination has the potential to become an improved prognostic assay for early-stage breast cancer.

scholarly journals Use of Autoantibodies to Detect the Onset of Breast Cancer

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Jérôme Lacombe ◽  
Alain Mangé ◽  
Jérôme Solassol
Keyword(s):  
Breast Cancer ◽  
Early Diagnosis ◽  
Early Stage ◽  
Tumor Development ◽  
Breast Cancer Diagnosis ◽  
Breast Disease ◽  
Screening Mammography ◽  
Early Stage Breast Cancer ◽  
Highly Sensitive Detection

The widespread use of screening mammography has resulted in increased detection of early-stage breast disease, particularly forin situcarcinoma and early-stage breast cancer. However, the majority of women with abnormalities noted on screening mammograms are not diagnosed with cancer because of several factors, including radiologist assessment, patient age, breast density, malpractice concerns, and quality control procedures. Although magnetic resonance imaging is a highly sensitive detection tool that has become standard for women at very high risk of developing breast cancer, it lacks sufficient specificity and costeffectiveness for use as a general screening tool. Therefore, there is an important need to improve screening and diagnosis of early-invasive and noninvasive tumors, that is,in situcarcinoma. The great potential for molecular tools to improve breast cancer outcomes based on early diagnosis has driven the search for diagnostic biomarkers. Identification of tumor-specific markers capable of eliciting an immune response in the early stages of tumor development seems to provide an effective approach for early diagnosis. The aim of this review is to describe several autoantibodies identified during breast cancer diagnosis. We will focus on these molecules highlighted in the past two years and discuss the potential future use of autoantibodies as biomarkers of early-stage breast cancer.

scholarly journals US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer

2011 ◽  
Vol 7 (3S) ◽  
pp. e38s-e45s ◽  
Author(s):  
John Hornberger ◽  
Rebecca Chien ◽  
Katie Krebs ◽  
Louis Hochheiser
Keyword(s):  
Breast Cancer ◽  
Clinical Utility ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Multigene Assay

This study presents Humana's experience with a multigene breast cancer assay and provides an analysis of the clinical utility and economics of this technology.

scholarly journals 144P A personalised sequencing approach for liquid biopsy-based detection of recurrent disease in early-stage breast cancer

2021 ◽  
Vol 32 ◽  
pp. S423
Author(s):  
W. Janni ◽  
J. Huober ◽  
S. Huesmann ◽  
C. Pipinikas ◽  
T. Braun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liquid Biopsy ◽  
Recurrent Disease ◽  
Early Stage ◽  
Early Stage Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document